Table 2 Immune responses in patients with kidney failure after four primary COVID-19 vaccine doses

From: Vaccination in patients with kidney failure: lessons from COVID-19

KRT

Vaccine

Humoral response after 2nd dose

Post-vaccination time (weeks)

Sample (n)

Binding humoral response (%)

Ref.

Tx

BNT162b2, mRNA-1273 and Ad26.COV2.S

Absent to high

2–6

18

83.3

141

Absent

6

50.0

Txa

mRNA-1273

Low

4

58

100.0

142

Tx

BNT162b2 and mRNA-1273

Absent to low

4

92

50.0

143

HD

BNT162b2

Absent to high

6–8

19

100.0

144

Tx

BNT162b2

Absent to low

4

37

51.4

145

Absent

31

41.9

Tx

BNT162b2 and others

Absent

5

49

42.9

146

Tx

BNT162b2, mRNA-1273, ChAdOx1-S and Ad26.COV2.S

Absent to high

2

250

55.6

147

Tx

Ad26.COV2.S

Absent to low

4

20

45.0

148

Absent

13

15.4

Tx

BNT162b2

Absent

4

29

76.0

149

  1. HD, haemodialysis; KRT, kidney replacement therapy; NA, not available; Tx, transplantation. Note that some studies only included patients without seroconversion after the second or third vaccine dose, whereas others also included patients with a low humoral response or even all patients regardless of their immune response. a63.8% of patients had a neutralizing response against the Delta SARS-CoV-2 variant.
Back to article page